Staffan Lindstrand

Directeur/Membre du Conseil chez OREXO AB Fortune : 83 654 $ au 31/05/2026

Profil

Staffan Lindstrand currently works at Doctrin AB, as Chairman, Orexo AB, as Independent Director from 2002, Technolas Perfect Vision GmbH, as Director, Swedish Association of Exchange Listed Cos., as Director, Gerner Holdings AB, as Director, Limehold AB, as Director, Severus SA, as Director, Elsa Science AB, as Director from 2021, Pactumize AB, as Director, and HealthCap AB, as Partner from 1997.
Mr. Lindstrand also formerly worked at Aerocrine AB, as Independent Director from 1999 to 2014, Inion Oy, as Director, Pulmonx Corp., as Independent Director, Biotage AB, as Director, Resistentia Pharmaceuticals AB, as Director, Newron Sweden AB, as Director, Creative Peptides Sweden AB, as Director, Direct Conversion AB, as Non-Executive Director, 20, as Director, OxThera AB, as Director, CDC, Inc., as Director, Oscars Forskola, as Director, Healthcap 1999 GP AB, as Director, and Abb Aros Securities, Inc., as Vice President from 1986 to 1997.
Mr. Lindstrand received his graduate degree from Royal Institute of Technology.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
OREXO AB 0,11 %	31/12/2025	37 678 ( 0,11 % )	83 654 $	31/05/2026

Postes actifs de Staffan Lindstrand

Sociétés	Poste	Début
OREXO AB	Directeur/Membre du Conseil	01/01/2002
HealthCap AB	Private Equity Investor	01/01/1997
Elsa Science AB	Directeur/Membre du Conseil	01/09/2021
Pactumize AB	Directeur/Membre du Conseil	-
Swedish Association of Exchange Listed Cos.	Directeur/Membre du Conseil	-
Doctrin AB	Président	-
Severus SA	Directeur/Membre du Conseil	-
Limehold AB	Directeur/Membre du Conseil	-
Gerner Holdings AB	Directeur/Membre du Conseil	-
░░░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	-

Anciens postes connus de Staffan Lindstrand

Sociétés	Poste	Fin
░░░░░░░░░ ░░░░ ░░ ░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░░░ ░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░ ░░░░░░░░░░ ░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░